Cathy Eng, MD, FACP, FASCO

home / authors / cathy-eng-md-facp-fasco

Articles

The Ideal Patient for Biomarker Testing in Anal Carcinoma

The Ideal Patient for Biomarker Testing in Anal Carcinoma

Cathy Eng, MD, FACP, FASCO
July 2nd 2022

Cathy Eng, MD, FACP, FASCO, discusses the types of patients who should be tested for biomarkers in the anal cancer space.

The Role of Biomarker Testing in Anal Cancer

The Role of Biomarker Testing in Anal Cancer

Cathy Eng, MD, FACP, FASCO
August 8th 2021

Cathy Eng, MD, FACO, FASCO, discusses how biomarkers are being explored to aid the treatment of anal cancers.

NTRK Fusion–Positive Colon Cancer: Final Thoughts

NTRK Fusion–Positive Colon Cancer: Final Thoughts

Cathy Eng, MD, FACP, FASCO
May 4th 2020
NTRK-Targeted Therapy in Colon Cancer: Dosing and Management

NTRK-Targeted Therapy in Colon Cancer: Dosing and Management

Cathy Eng, MD, FACP, FASCO
May 4th 2020
NTRK-Targeted Therapy for Patients With Colon Cancer

NTRK-Targeted Therapy for Patients With Colon Cancer

Cathy Eng, MD, FACP, FASCO
May 4th 2020
Treatment Options for NTRK Fusion–Positive mCRC

Treatment Options for NTRK Fusion–Positive mCRC

Cathy Eng, MD, FACP, FASCO
May 4th 2020
Testing for NTRK Fusion–Positive Metastatic Colon Cancer

Testing for NTRK Fusion–Positive Metastatic Colon Cancer

Cathy Eng, MD, FACP, FASCO
May 4th 2020
Case-Based Overview: NTRK Fusion–Positive mCRC

Case-Based Overview: NTRK Fusion–Positive mCRC

Cathy Eng, MD, FACP, FASCO
May 4th 2020
A 68-Year-Old Woman with Metastatic NTRK Fusion-Positive Colon Cancer

A 68-Year-Old Woman with Metastatic NTRK Fusion-Positive Colon Cancer

Cathy Eng, MD, FACP, FASCO
May 4th 2020

Cathy Eng, MD, FACP, FASCO, reviews the case of a 68-year-old diagnosed with metastatic NTRK fusion-positive colon cancer and shares treatments options.

Latest Updated Articles

ASH 2024 Preview for Community Oncologists: The Show and After Show
Published: December 3rd 2024 | Updated: December 6th 2024
ASH 2024 Preview for Community Oncologists: The Show and After Show
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
Published: May 6th 2024 | Updated: May 21st 2024
FDA Accepts BLA for Subcutaneous Nivolumab Across Various Solid Tumors
When to Stop or Switch JAK Inhibitor Therapy in Myelofibrosis
Published: December 12th 2022 | Updated: December 24th 2024
When to Stop or Switch JAK Inhibitor Therapy in Myelofibrosis
SEQUOIA Trial: Updates from ASH 2024
Published: December 21st 2024 | Updated: December 24th 2024
SEQUOIA Trial: Updates from ASH 2024
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
Published: December 20th 2024 | Updated: December 24th 2024
Therapy Type and Site of Metastases Factor into HR+, HER2+ mBC Treatment
Bridging Options for CAR T-Cell Therapy in R/R DLBCL
Published: January 6th 2023 | Updated: December 24th 2024
Bridging Options for CAR T-Cell Therapy in R/R DLBCL